Transplant May Still Benefit CML Patients Experiencing TKI Resistance

When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.

The need for allogeneic stem cell transplant in chronic myeloid leukemia (CML) patients has decreased due to tyrosine kinase inhibitor (TKI) use. But when CML patients develop resistance or intolerance to these drugs, transplant may be the only option.

This study was recently published in the journal Clinical Lymphoma, Myeloma & Leukemia and presented (abstract CML-193) at the Society of Hematologic Oncology meeting, held September 7-11, 2016, in Houston.